Title: Results of RELIEF, a Phase 2a study with BLU-5937 in Refractory Chronic Cough
Details: The presentation will highlight nominal effect size and baseline characteristics of the ITT population in the RELIEF trial, as well as for two pre-specified sub-groups (≥20 coughs per hour at baseline and ≥32 coughs per hour at baseline).
Session: Clinical trials of antitussive therapies
Time: 1:00 –
Title: BLU-5937, A Potent and Selective P2X3 Receptor Antagonist, Presents a Promising New Approach for the Treatment of Chronic Pruritus in Atopic Dermatitis Patients
Details: The presentation will highlight preclinical data that support the potential efficacy of P2X3 antagonists in the treatment of atopic dermatitis-derived pruritus.
Session: Migraine, itch and chronic cough (Q&A session)
Time: 3:45 –
Following the conference, the presentations will be available in the “Scientific Publications” section of
Chronic cough, the lead indication for BLU-5937, is a cough lasting more than eight weeks and is associated with significant adverse physical, social and psychosocial effects on health and quality of life. It is estimated that approximately 26 million adults in
Chronic pruritus, the second indication for BLU-5937, is commonly known as chronic itch and is an irritating sensation that leads to scratching and persists for longer than six weeks, which can be debilitating and can significantly impact quality of life. It is a hallmark of many inflammatory skin diseases, including atopic dermatitis (“AD”). It is estimated that AD afflicts approximately 5% of adults in the United States. Despite currently available treatments targeting AD, there continues to be a lack of options targeting the burden of pruritus in AD patients.
Director, Investor Relations and Communications